StoryFunding
YolTech completes $45M Series B funding round led by AstraZeneca-CICC fund
YolTech raised $45 million in Series B funding led by the AstraZeneca-CICC healthcare investment fund in September 2025, supporting clinical development of YOLT-101.
- Series B round totaled $45 million, led by AstraZeneca-CICC fund.
- Funding accelerated YOLT-101 advancement toward global clinical trials.
- Demonstrated investor confidence in YolTech's base-editing platform.